Previous 10 | Next 10 |
2023-10-30 08:34:25 ET Miromatrix Medical ( MIRO ) +225% to buy Miromatrix Medical for $3.25 per share, MIRO jumps 225%. TD Holdings ( BYU ) +63% . Conduit Pharmaceuticals ( CDT ) +56% . VYNE Therapeutics Inc ( VYNE ) +47% jumps 52% on posit...
2023-10-25 13:11:55 ET Gainers: Abri SPAC I ( ASPA ) +154% . Jaguar Global Growth Corp I ( JGGC ) +88% . Nuvve Holding Corp ( NVVE ) +44% . Data Knights Acquisition Corp ( DKDCA ) +42% . Werewolf Therapeutics ( HOWL ) +28% . ...
Six abstracts, spanning Werewolf’s PREDATOR™ platform and INDUKINE™ pipeline, accepted for poster presentations at SITC annual meeting Company to present interim first-in-human clinical data from initial monotherapy dose-escalation cohorts in ongoing Phase 1/1b study of W...
WATERTOWN, Mass., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body...
WATERTOWN, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body...
2023-08-24 13:04:58 ET A Massachusetts-based biotech company is turning heads on Thursday after it was announced that Webush Securities initiated coverage on the stock with an outperform rating and a $9.00 price target. Seeing that the stock closed at just $2.58 yesterday, naturally traders...
2023-08-24 12:05:42 ET More on Werewolf Werewolf assumed Buy at Jefferies ahead of data for key cancer drug Werewolf Therapeutics jumps ~10% after RA Capital ups stake, says may engage in talks Werewolf Therapeutics stock rises as HC Wainwright places Buy rating over...
2023-08-10 10:32:34 ET Werewolf Therapeutics press release ( NASDAQ: HOWL ): Q2 GAAP EPS of -$0.14 beats by $0.27 . Revenue of $8.08M (+94.7% Y/Y) beats by $4.93M . For further details see: Werewolf Therapeutics GAAP EPS of -$0.14 beats by $0.27, revenue ...
- Phase 1/1b clinical trial for IL-2 INDUKINE™ WTX-124 progressing in patients with advanced or metastatic solid tumors; initial first-in-human clinical data from monotherapy dose-escalation arm expected in 4Q 2023 - - Phase 1 clinical trial for IL-12 INDUKINE WTX-330 progressing...
2023-08-01 15:49:41 ET Summary MDNA failed to report data from the fifth dosing cohort, of its phase 1/2 ABILITY study of MDNA11, in Q2'23 as expected. The company is instead presenting data from both the fifth and sixth cohorts of the trial on August 9, 2023. MDNA has cash to...
News, Short Squeeze, Breakout and More Instantly...
Werewolf Therapeutics Inc. Company Name:
HOWL Stock Symbol:
NASDAQ Market:
Werewolf Therapeutics Inc. Website:
- Data demonstrate that administration of WTX-330 reached therapeutically relevant exposure levels of systemically delivered IL-12 prodrug with an improved tolerability profile over historical data for rhIL-12 - - Early WTX-330 dose-escalation data demonstrated encouraging clinical acti...
- WTX-124 was shown to be clinically active and generally well-tolerated in patients who were relapsed/refractory to immune checkpoint inhibitor therapy - - Encouraging single agent clinical activity with three objective responses, including a durable confirmed complete respon...
WATERTOWN, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body ...